mipetresgene autoleucel

迈基仑赛

Report date: 2025/09/17 20:01:18

Base Information

Drug Namemipetresgene autoleucel
Drug Alias NameNY-ESO-1 antigen-specific RetroNectin TCR gene therapyNY-ESO-1 antigen-specific TCR-gene-transduced autologous lymphocytesTBI-1301
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > MMLV vector +[4] 
Mechanisms of ActionImmunostimulantsCancer/testis antigen 1 modulatorsGene transference
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaJapan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakara Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio IncMie UniversityOtsuka Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A